Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.
Authors' Affiliations: Lady Davis Institute & Segal Cancer Centre of the Jewish General Hospital, McGill University; Institute for Research in Immunology and Cancer & Department of Pathology and Cell Biology, Université de Montréal, Montréal, Quebec, Canada; Buck Institute for Age Research, Novato, California; and Dana-Farber Cancer Institute, Boston, Massachusetts.
We have evaluated the eukaryotic translation initiation factor 4E (eIF4E) as a potential biomarker and therapeutic target in breast cancer. eIF4E facilitates nuclear export and translation of specific, growth-stimulatory mRNAs and is frequently overexpressed in cancer.
Clin. Cancer Res. 2011;17(9):2874-84.
Pubmed ID: 21415224